{"id":18847,"date":"2024-05-26T20:59:58","date_gmt":"2024-05-26T18:59:58","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&#038;p=18847"},"modified":"2026-04-18T11:23:32","modified_gmt":"2026-04-18T09:23:32","slug":"tirzepatide-15mg","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/product\/tirzepatide-15mg\/","title":{"rendered":"GLP1+GIP 15 mg vial"},"content":{"rendered":"<div data-elementor-type=\"product-post\" data-elementor-id=\"18847\" class=\"elementor elementor-18847\" data-elementor-post-type=\"product\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5398a95 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"5398a95\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b04e45a\" data-id=\"b04e45a\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-eff25d0 elementor-widget elementor-widget-text-editor\" data-id=\"eff25d0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h2 data-start=\"242\" data-end=\"313\">Thirzepatide 15mg - chemical structure and molecular characterization<\/h2><p data-start=\"315\" data-end=\"569\">Tirzepatide 15mg is a synthetic peptide designed as a dual GLP-1R and GIPR receptor agonist. The molecule consists of a modified amino acid sequence linked to a lipid chain that allows reversible binding to albumin.<\/p><p data-start=\"571\" data-end=\"790\">The use of structural modifications (including amino acid substitutions to increase resistance to enzymatic degradation and acylation) prolongs half-life and metabolic stability in the biological environment.<\/p><p data-start=\"792\" data-end=\"965\">The molecular weight of tirzepatydu is about 4813 Da, which classifies it as a high-molecular-weight complex peptide, typical of new-generation incretin analogs.<\/p><p data-start=\"967\" data-end=\"1202\">Structural studies indicate that the molecule's conformation allows selective binding to the transmembrane domains of GLP-1R and GIPR receptors, leading to activation of intracellular Gs protein-dependent signaling and an increase in cAMP.<\/p><hr data-start=\"1204\" data-end=\"1207\" \/><h2 data-start=\"1209\" data-end=\"1257\">Thirzepatide 15mg as a laboratory reagent<\/h2><p data-start=\"1259\" data-end=\"1372\">In the research community, tirzepatide 15mg is used as a reference material in projects on:<\/p><ul data-start=\"1374\" data-end=\"1546\"><li data-start=\"1374\" data-end=\"1414\"><p data-start=\"1376\" data-end=\"1414\">Incretin receptor pharmacology,<\/p><\/li><li data-start=\"1415\" data-end=\"1435\"><p data-start=\"1417\" data-end=\"1435\">GPCR signaling,<\/p><\/li><li data-start=\"1436\" data-end=\"1478\"><p data-start=\"1438\" data-end=\"1478\">Regulation of glucose and lipid metabolism,<\/p><\/li><li data-start=\"1479\" data-end=\"1546\"><p data-start=\"1481\" data-end=\"1546\">Integration of appetite and energy balance control mechanisms.<\/p><\/li><\/ul><p data-start=\"1548\" data-end=\"1683\">Dual receptor activation allows us to analyze the synergistic effects of the GIP\/GLP-1 axis in cellular and preclinical models.<\/p><p data-start=\"1685\" data-end=\"1872\">In vitro studies have shown that activation of these receptors leads to an increase in cAMP, modulation of gene expression related to glucose metabolism, and effects on mitochondrial activity.<\/p><hr data-start=\"1874\" data-end=\"1877\" \/><h2 data-start=\"1879\" data-end=\"1922\">Tirzepatide 15mg in clinical trials<\/h2><p data-start=\"1924\" data-end=\"2014\">The 15 mg dose was the highest weekly dose analyzed in phase III clinical programs.<\/p><p data-start=\"2016\" data-end=\"2114\">In the study <strong data-start=\"2026\" data-end=\"2040\">SURMOUNT-1<\/strong> published in <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">New England Journal of Medicine<\/span><\/span> (2022) reported:<\/p><ul data-start=\"2116\" data-end=\"2271\"><li data-start=\"2116\" data-end=\"2170\"><p data-start=\"2118\" data-end=\"2170\"><strong>Average weight reduction of ~20.9% after 72 weeks,<\/strong><\/p><\/li><li data-start=\"2171\" data-end=\"2222\"><p data-start=\"2173\" data-end=\"2222\"><strong>\u226520% weight reduction in more than 50% participants,<\/strong><\/p><\/li><li data-start=\"2223\" data-end=\"2271\"><p data-start=\"2225\" data-end=\"2271\"><strong>Improving lipid and glycemic parameters.<\/strong><\/p><\/li><\/ul><p data-start=\"2273\" data-end=\"2385\">In the program <strong data-start=\"2285\" data-end=\"2298\">SURPASS-2<\/strong> showed a significant reduction in HbA1c compared to the <span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">Semaglutide<\/span><\/span>.<\/p><p data-start=\"2387\" data-end=\"2514\">The safety profile was dose-dependent, and the most commonly reported side effects were gastrointestinal.<\/p><hr data-start=\"2516\" data-end=\"2519\" \/><h2 data-start=\"2521\" data-end=\"2560\">Significance in preclinical models<\/h2><p data-start=\"2562\" data-end=\"2628\">In preclinical studies, tirzepatide 15 mg provides a model for analysis:<\/p><ul data-start=\"2630\" data-end=\"2796\"><li data-start=\"2630\" data-end=\"2699\"><p data-start=\"2632\" data-end=\"2699\">Dose-response relationship at maximum receptor activation,<\/p><\/li><li data-start=\"2700\" data-end=\"2739\"><p data-start=\"2702\" data-end=\"2739\">integrating incretin signaling,<\/p><\/li><li data-start=\"2740\" data-end=\"2796\"><p data-start=\"2742\" data-end=\"2796\">The effects of GIPR and GLP-1R activation on tissue metabolism.<\/p><\/li><\/ul><p data-start=\"2798\" data-end=\"3001\">In animal models, changes in the expression of genes related to lipid metabolism and regulation of carbohydrate metabolism have been observed, which is interpreted as an effect of integrated hormonal modulation.<\/p><hr data-start=\"3003\" data-end=\"3006\" \/><h2>Nature of the product<\/h2><p data-start=\"3030\" data-end=\"3292\">Tirzepatide 15 mg offered in the laboratory market is a reference material intended for research and analytical use only (Research Use Only). It is not intended for therapeutic use outside of controlled clinical trials.<\/p><hr data-start=\"3294\" data-end=\"3297\" \/><p data-start=\"3299\" data-end=\"3315\"><a href=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial.png\"><img fetchpriority=\"high\" decoding=\"async\" class=\"aligncenter wp-image-35010 size-medium\" src=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-300x225.png\" alt=\"Tirzepatide 15mg vial \u2013 dual GIP\/GLP-1 research peptide\" width=\"300\" height=\"225\" srcset=\"https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-300x225.png 300w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-768x576.png 768w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-16x12.png 16w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-800x600.png 800w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial-64x48.png 64w, https:\/\/tirzepatyd.eu\/wp-content\/uploads\/2026\/02\/tirzepatide-15-mg-vial.png 1024w\" sizes=\"(max-width: 300px) 100vw, 300px\" \/><\/a><\/p><p data-start=\"3299\" data-end=\"3315\">Scientific sources:<\/p><ol data-start=\"3317\" data-end=\"3806\"><li data-start=\"3317\" data-end=\"3491\"><p data-start=\"3320\" data-end=\"3491\">Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity.<br data-start=\"3394\" data-end=\"3397\" \/><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">New England Journal of Medicine<\/span><\/span>, 2022.<br data-start=\"3444\" data-end=\"3447\" \/><a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/\" target=\"_new\" rel=\"noopener\" data-start=\"3450\" data-end=\"3491\">https:\/\/pubmed.ncbi.nlm.nih.gov\/35658024\/<\/a><\/p><\/li><li data-start=\"3493\" data-end=\"3685\"><p data-start=\"3496\" data-end=\"3685\">Fr\u00edas JP et al. Thirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.<br data-start=\"3588\" data-end=\"3591\" \/><span class=\"hover:entity-accent entity-underline inline cursor-pointer align-baseline\"><span class=\"whitespace-normal\">New England Journal of Medicine<\/span><\/span>, 2021.<br data-start=\"3638\" data-end=\"3641\" \/><a class=\"decorated-link\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/\" target=\"_new\" rel=\"noopener\" data-start=\"3644\" data-end=\"3685\">https:\/\/pubmed.ncbi.nlm.nih.gov\/34170647\/<\/a><\/p><\/li><li data-start=\"3687\" data-end=\"3806\"><p data-start=\"3690\" data-end=\"3806\">Min T. et al. Mechanisms of dual GIP\/GLP-1 receptor agonism.<br data-start=\"3750\" data-end=\"3753\" \/><a class=\"decorated-link\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10107501\/\" target=\"_new\" rel=\"noopener\" data-start=\"3756\" data-end=\"3806\">https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC10107501\/<\/a><\/p><\/li><\/ol><hr data-start=\"3294\" data-end=\"3297\" \/><p><strong>Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p><strong data-start=\"131\" data-end=\"152\">Tirzepatide 15 mg<\/strong> is an advanced peptide belonging to the group of dual GIP and GLP-1 receptor agonists. The molecule was designed for high metabolic stability and precise activation of incretin pathways in experimental models.<\/p>","protected":false},"featured_media":35010,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[124,111,15],"product_tag":[136],"class_list":{"0":"post-18847","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-fiolce","7":"product_cat-glp1gip","8":"product_cat-laboratory-research","9":"product_tag-fiolka","11":"first","12":"instock","13":"shipping-taxable","14":"purchasable","15":"product-type-simple"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=18847"}],"version-history":[{"count":12,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18847\/revisions"}],"predecessor-version":[{"id":35464,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18847\/revisions\/35464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/35010"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=18847"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=18847"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=18847"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=18847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}